Welcome to our dedicated page for MoonLake Immunotherapeutics SEC filings (Ticker: MLTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MoonLake Immunotherapeutics (NASDAQ: MLTX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as it develops sonelokimab, an investigational Nanobody® targeting IL‑17A and IL‑17F, for inflammatory skin and joint diseases. As a Cayman Islands–incorporated issuer listed on Nasdaq, MoonLake files reports and current event disclosures with the Securities and Exchange Commission that document material agreements, clinical milestones and financial results.
Among the key documents are Form 8‑K filings, which MoonLake uses to report material events such as the pricing of an underwritten offering of Class A ordinary shares, entry into a term loan facility, and press releases announcing quarterly financial results. 8‑K filings also reference clinical and regulatory developments, including Phase 3 VELA trial data in hidradenitis suppurativa (HS), Phase 2 LEDA results in palmoplantar pustulosis (PPP), interim analyses from the VELA‑TEEN adolescent HS study, and updates on the broader sonelokimab trial portfolio.
Investors can use this page to review how MoonLake describes its financial condition, capital structure and key agreements in official SEC documents. Filings may incorporate press releases that summarize cash balances, research and development spending, non-dilutive financing arrangements, and expectations regarding the funding of Phase 2 and Phase 3 programs in HS, psoriatic arthritis (PsA), axial spondyloarthritis (axSpA) and PPP.
Stock Titan enhances these filings with AI-powered tools that help interpret lengthy disclosures. Users can quickly identify the purpose of a given 8‑K, locate references to clinical trial data, and understand the context of equity offerings or debt facilities. Real-time updates from EDGAR ensure that new MoonLake filings appear promptly, while structured access makes it easier to follow how regulatory, clinical and financing developments are reflected in the company’s official record.
MoonLake Immunotherapeutics is a clinical-stage biotech focused on a single asset, sonelokimab (SLK), a tri-specific IL‑17A/IL‑17F Nanobody for inflammatory skin and joint diseases. The company is targeting hidradenitis suppurativa (HS), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), palmoplantar pustulosis (PPP) and related IL‑17‑driven conditions.
Phase 3 HS trials (VELA‑1 and VELA‑2) showed clinically meaningful HiSCR75 responses and consistent safety, supporting plans to submit a Biologics License Application for adult and adolescent HS in the second half of 2026, with a potential first U.S. launch in the second half of 2027, subject to approval. A Phase 3 adolescent HS study (VELA‑TEEN) reported strong interim responses.
In PsA, the Phase 2b ARGO trial delivered high ACR and PASI response rates versus placebo and an adalimumab reference arm, and two global Phase 3 trials (IZAR‑1 and IZAR‑2) are underway with key readouts expected in 2026. Phase 2 data in PPP (LEDA) and axSpA (S‑OLARIS) also showed substantial symptom improvements, and SLK obtained FDA Fast Track designation in moderate‑to‑severe PPP. MoonLake relies on third‑party manufacturing and an exclusive license from Merck Healthcare KGaA and expects to invest further in commercialization, manufacturing, and intellectual property as it advances SLK toward potential approval.
MoonLake Immunotherapeutics entered into an amended senior secured term loan facility totaling
The amended agreement adds a conditional revenue covenant if the fifth tranche is used, but has no scheduled amortization and allows full prepayment with declining fees. MoonLake also reported positive Phase 2 S-OLARIS data in axial spondyloarthritis, with
As of December 31, 2025, the company held
Cormorant Asset Management, LP and Bihua Chen have disclosed a significant ownership stake in MoonLake Immunotherapeutics. They report beneficial ownership of 4,355,433 Class A ordinary shares, representing 6.10% of the class. All voting and investment power over these shares is shared, with no sole voting or dispositive authority.
The filing states that the securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of MoonLake Immunotherapeutics. The report is made jointly by Cormorant Asset Management, LP and Bihua Chen under Schedule 13G rules.
MoonLake Immunotherapeutics reported that its Chief Financial Officer, Matthias Bodenstedt, received an award of 354,296 Class A ordinary shares on January 7, 2026. The shares were granted at a price of $0 per share as restricted stock, meaning they are subject to vesting conditions rather than being fully transferable immediately.
According to the filing, these restricted shares will vest in four equal annual installments on January 7, 2027, 2028, 2029 and 2030, as long as he continues to serve the company through each vesting date. After this grant, Bodenstedt beneficially owned a total of 1,276,305 Class A ordinary shares, all held directly.
MoonLake Immunotherapeutics reported that Chief Executive Officer and director Jorge Santos da Silva received a new stock option award. On January 7, 2026, he was granted an option to buy 520,342 Class A ordinary shares at an exercise price of $11.29 per share. The option runs until January 7, 2036.
These options vest over time, rather than all at once. The award vests in four equal annual installments on January 7, 2027, 2028, 2029 and 2030, and each vesting installment requires his continued service with the company through the relevant date. The filing shows he holds these derivative securities directly.
MoonLake Immunotherapeutics reported an equity award to a senior executive. Chief Scientific Officer Kristian Reich filed a Form 4 showing a grant of stock options covering 520,342 Class A ordinary shares at an exercise price of
The options were granted on
MoonLake Immunotherapeutics reported that it received positive feedback from the U.S. Food and Drug Administration on the clinical evidence strategy for its drug candidate Sonelokimab (SLK) in hidradenitis suppurativa, following a requested Type B FDA meeting. This feedback relates to how the company is generating the clinical data needed to support SLK in this indication.
The company also plans to hold an Investor Day on February 23, 2026 at 8:00 a.m. Eastern Time to discuss the outcomes of the Type B FDA meeting in more detail and to present new clinical data for SLK across multiple indications. A press release with these updates was filed as an exhibit to this report.
MoonLake Immunotherapeutics entered an underwriting agreement to sell 7,142,857 Class A ordinary shares at $10.50 per share. The transaction is expected to generate gross proceeds of $75 million before underwriting discounts and offering expenses.
The shares are being issued under an effective Form S-3 shelf (File No. 333-274286), with a prospectus supplement dated November 5, 2025. Closing is expected on November 6, 2025, subject to customary closing conditions. The company agreed to customary indemnification provisions in favor of the underwriter, Leerink Partners LLC.
MoonLake Immunotherapeutics is offering 7,142,857 Class A Ordinary Shares at $10.50 per share pursuant to a prospectus supplement. The company estimates net proceeds of approximately $72.6 million after underwriting discounts and offering expenses, to be used to fund research and development of SLK and for general corporate purposes. The company expects these funds, together with existing cash and investments, to be sufficient to fund its planned Phase 3 clinical trial in PPP.
Gross proceeds are $74,999,999, with underwriting discounts and commissions of $2,250,000. Shares outstanding were 64,230,722 as of September 30, 2025, and are expected to be 71,373,579 after this offering. New investors will experience immediate dilution of $5.40 per share based on the as adjusted net tangible book value as of September 30, 2025. A 60‑day lock‑up applies to the company, directors, officers and certain holders. MLTX last traded at $10.13 on November 4, 2025. Leerink Partners is the sole bookrunning manager, with delivery expected on or about November 6, 2025.
MoonLake Immunotherapeutics reported third-quarter 2025 results showing higher R&D investment and a wider loss as it advances sonelokimab. R&D expenses were $60.6M and total operating expenses reached $71.4M, leading to a net loss of $70.7M for the quarter and $167.3M year-to-date. Interest expense was $3.2M, reflecting new debt.
Liquidity remains strong with cash and cash equivalents of $350.7M and short‑term marketable securities of $29.7M. Management states this resources base funds operations into the second half of 2027. Shareholders’ equity was $288.9M, and long‑term debt stood at $73.7M following a $75M initial draw under a $500M credit facility.
Clinical progress was mixed: the company announced that VELA‑1 met its primary endpoint in hidradenitis suppurativa, while a higher‑than‑expected placebo response prevented VELA‑2 from meeting its pre‑specified primary endpoint. As a result, the company did not achieve certain loan milestones tied to additional tranches under the facility.